Results 141 to 150 of about 63,797 (281)

The Renal Activity Index for Lupus Identifies Active Renal Disease and Treatment Response in Adult Patients With Systemic Lupus Erythematosus and Lupus Nephritis

Arthritis Care &Research, Volume 78, Issue 6, Page 723-732, June 2026.
Objective We evaluated the ability of the Renal Activity Index for Lupus (RAIL) to discriminate active lupus nephritis (LN) in adult patients with active systemic lupus erythematosus (SLE) and differentiate LN treatment response. Methods Urine samples from adults with biopsy‐proven active class III and IV LN from TULIP‐LN (active LN group ...
Hermine I. Brunner, Ellen M. Cody, Prasad Devarajan, Bin Huang, Chen Chen, Dominic Sinibaldi, Madhu Ramaswamy, Jacob Knagenhjelm, Frederick Jones, Philip Z. Brohawn, Raj Tummala, Catharina Lindholm, Wendy I. White   +12 more
wiley   +1 more source

Clinical spectrum and management outcomes of acute febrile illness Among children attending health facilities in northwestern Tanzania, 2020-2021. [PDF]

Front Pediatr
Kayange NM, Malande OO, Gehring S, Scialabba S, Groendahl B, Koliopoulos P, Mshana SE.   +6 more
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Volume 78, Issue 6, Page 761-770, June 2026.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Correction: Machine learning-based phenotypic imaging to characterise the targetable biology of Plasmodium falciparum male gametocytes for the development of transmission-blocking antimalarials. [PDF]

PLoS Pathog
Tsebriy O, Khomiak A, Miguel-Blanco C, Sparkes PC, Gioli M, Santelli M, Whitley E, Gamo FJ, Delves MJ.   +8 more
europepmc   +1 more source

Long‐Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus

ACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Objective To evaluate the long‐term effects of anifrolumab on hematologic and serologic parameters over four years. Methods This analysis included 536 patients with moderate‐to‐severe systemic lupus erythematosus (SLE) who received intravenous anifrolumab 300 mg (n = 358) or placebo (n = 178) in the 52‐week, phase 3 TULIP‐1/2 trials (NCT02446912 and ...
Edward M. Vital, Zahir Amoura, Kenneth C. Kalunian, Ian N. Bruce, Yoshiya Tanaka, Susan Manzi, Ihor Hupka, Jacob Knagenhjelm, Hussein Al‐Mossawi, Catharina Lindholm   +9 more
wiley   +1 more source

Positive tests are all alike, every negative test is negative in its own way: lack of confidence in negative malaria rapid diagnostic tests in the Democratic Republic of the Congo. [PDF]

Malar J
Sugg KN, Mpata FW, Humes MD, Aliango Marachto D, Rajan R, Winch PJ.   +5 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1258-1267, June 2026.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

4-Aminoquinolines block heme iron reactivity and interfere with artemisinin action. [PDF]

Elife
Rosenthal M, Goldberg DE.
europepmc   +1 more source

Novel antimalarial targets and the antimalarial pipeline [PDF]

International Journal of Infectious Diseases, 2014
openaire   +2 more sources

A link between poor quality antimalarials and malaria drug resistance?

Expert Review of Anti-Infective Therapy, 2016
P. Newton, C. Caillet, P. Guérin
semanticscholar   +1 more source